American Diabetes Association 81st Scientific Sessions

June 25-29, 2021; Virtual; Resource Hub

Welcome to our ADA 2021 resource hub! This is a one-stop shop for all your ADA 2021 needs. We'll post all of our ADA-related documents as we publish them, so check back often.

Useful Conference Links

• Conference Website

• Conference registration

• Day-by-Day Conference Preview

• Program

• Mobile App

• Embargo Policy

Diabetes Therapy Highlights

• Full SURPASS-2 Results for Lilly’s GLP-1/GIP Tirzepatide vs. Novo Nordisk’s Semaglutide Published in NEJM; 60% of Participants on 15 mg Achieve A1c ≤6.5% and 10% Weight Loss, Without Hypoglycemia

• Type 1 Cures Alert: ViaCyte’s PEC-Direct Islet Therapy (n=1) Achieves 0.8 ng/ml Stimulated C-Peptide and +34% Increase of Time in Range

• AZ’s Once-Weekly GLP-1 Exenatide Delivers Promising Results in Youth with Type 2

• FIDELIO-DKD Analysis Highlights Efficacy of Finerenone on Top of SGLT-2 Inhibitor Use, Fueling Promise of Combination Therapy in DKD

• Phase 2 Trial Suggests Afrezza is Safe and Effective for Pediatric Patients with Type 1 Diabetes, Phase 3 to Launch in 4Q21

• Experts Sound Off on SGLT-2s/GLP-1s for Hospitalized Patients: Prescribe ASAP or Prescribe at Discharge?

• Newest Insights on HF & CKD: Preventive HF Medicine, SGLT-2 Inhibitors Reign Supreme in CKD, and Strong Rationale for Combo GLP-1/SGLT-2 Inhibitor Usage

• MannKind Poster Shows Afrezza Inhaled Insulin Leads to Significant Increases in Daytime Time in Range for Uncontrolled Type 2s

• Ex-Sanofi GLP-1’s Second Act? Efpeglenatide Meets Primary Endpoint in Phase 3 AMPLITUDE-M Monotherapy Trial  

• Next STEP Forward: STEP Symposium Highlight Potential of Semaglutide 2.4 mg Across Continuum of Diabetes and Obesity, Substantial Reduction of Pre-Diabetes in People with Overweight/Obesity

• KOLs Debate Semaglutide 2.4 mg vs. 1.0 mg During Q&A; Dr. Julio Rosenstock Calls for Use as First Line Therapy in Newly Diagnosed Diabetes for Remission

• SURPASS-1 Monotherapy Trial Results for Lilly’s GLP-1/GIP Tirzepatide in Type 2 Diabetes Published in The Lancet along with commentary "Tirzepatide and the new era of twincretins for diabetes" - both dated June 26, 2021

• Novo Nordisk’s Semaglutide 2.0 mg Outperforms 1.0 mg Dose Across Baseline A1cs and Body Weights in Type 2 Diabetes; SUSTAIN FORTE Full Results in Press at The Lancet Diabetes & Endocrinology (press release here, with an interview following shortly with Novo Nordisk's Dr. Michael Radin)

• New DAPA-CKD Analysis Shows Lower Incidence of New-Onset Diabetes with SGLT-2 dapagliflozin vs. Placebo; Raises Questions around Potential Prediabetes Indication

• AZ GLP-1/Glucagon Receptor Agonist Cotadutide Delivers +15% Time in Range and Early Evidence of Renal Protection in Phase 2 DKD Trial; Advanced to Phase 2b vs. Semaglutide 1.0 mg

• AZ’s Cotadutide Phase 2 Results Show the GLP-1/Glucagon Dual Agonist Confers Weight Loss by Reducing Energy Intake

• Dr. Muthiah Vaduganathan Concludes SGLT-2 Inhibitors Show Promise in Treating HFpEF But Will Face Challenges Showing “Disease-modifying” Potential in Reducing Mortality 

• Barrage of STEP 2 Data Support High-Dose Semaglutide’s Benefit in Diabetes and Obesity

• DARE-19 Symposium: Dapagliflozin Safe in Patients Hospitalized with COVID-19; Trend Toward Benefit on Organ Failure + Death Raises Question of a Future in Critical Illness

• New Insights on FIDELIO-DKD: Cardiorenal Benefits of MRA Finerenone Profound Across Baseline A1c

• Once-Weekly CGM Data Further Bolsters Safety and Efficacy of Lilly’s Phase 2 Once-Weekly Basal Insulin-FC in Type 2 Diabetes

• Length of Hypoglycemia Duration Consistent Between Novo Nordisk’s Once-Weekly Insulin Icodec and IGlar U100 in Type 2 Diabetes

• Drs. Bakris, Fonseca, and Nicholas Rally Behind Finerenone’s Potential to Slow Nephropathy and Delay Dialysis for Type 2 Diabetes Patients with CKD

• Results from Phase 2 MemAID Trial of Intranasal Insulin on Cognition Led to Faster Walking Speed, Lower Insulin Resistance, and Higher Cerebral Blood Flow in Participants with T2D

• AMPLITUDE-O Full Results: GLP-1 Efpeglenatide Delivers 27% RRR on MACE, Becoming First Exendin-Based GLP-1 to Find CVOT Success in Patients with Type 2 and CV/Renal Disease

• Making the GRADE: Preliminary Results from Head-to-Head GRADE Study (n=5,047, Five Year Duration) Reveal Liraglutide and Insulin Glargine Beat Out Glimepiride and Sitagliptin on A1c; Role of DPP-4 Inhibitors in Question?

• Soliqua (Insulin Glargine/Lixisenatide) Shows Superior A1c Reductions and Weight Loss Over Premixed Insulin in SoliMix Readout

• Dr. Jeremy Pettus Unveils Impressive A1c and TIR Results for Glucagon Receptor Antagonist Antibody Volagidemab (REMD-477) as a T1D Adjunct Therapy

• SGLT-2 Inhibition or GLP-1 Agonism for Cardioprotection? In Real-World Analysis, SGLT-2s Come Out Ahead

• Tirzepatide Delivers Mixed PROs in SURPASS-1: Improvements on Select Health-Related Quality of Life Measures and Weight Perception vs. Placebo, Not Physical Activity

• SOLOIST/SCORED Symposium Closes Out ADA: SGLT-1/2 Inhibitor Sotagliflozin Delivers Significant Early CV Benefit in Pooled Analysis; KOLs Ask for Head-to-Head vs. SGLT-2 Inhibitor to Clarify Role of SGLT-1

• SURPASS Symposium: KOLs Debate GLP-1 vs. GIP Contributions to Tirzepatide’s Standout Weight Loss and A1c Efficacy, Position Tirzepatide and Semaglutide 2.4 mg as Equally “Excellent Molecules”

• New Findings from DAPA-CKD: AZ’s SGLT-2 Farxiga Gives Consistent Renal & CV Benefits across Subgroups with Normoglycemia, Prediabetes, Type 2 Diabetes

• Dr. Nasrien Ibrahim Highlights Four Potential Therapies for HFpEF; Dr. Michelle Kittleson Strongly Recommends HFrEF Quadruple Therapy with Rapid Sequential Initiation

• Type 1 Cures Alert: Six Out of Seven Participants Show Successful Sernova Cell Pouch Implantation and Tolerance in Phase 1/2 Trial; Majority Show Increased C-Peptide

Diabetes Technology Highlights

• Retrospective EHR Analysis Shows Nearly Identical A1c Reductions and Acute Diabetes Event Rates in Type 1s and Type 2s Using Abbott’s FreeStyle Libre vs. Dexcom’s G5 or G6 CGM

• Abbott Poster Estimates Adding FreeStyle Libre to Medicaid Formularies is Essentially Cost Neutral (~$19 Million in Annual Cost Savings); Dr. Irl Hirsch Revises CGM-Driven DKA Cost Savings to $4.8 Billion (!)

• Type 2s Using Dexcom G6 in Onduo’s Virtual Diabetes Clinic (n=354) See 0.7% A1c Reduction to 7.2% at One Year, A Significantly Greater Improvement Than Non CGM-Users (n=418); Whopping 2.8% Reduction for CGM Users with Baseline A1c’s >9%

• Onduo Virtual Diabetes Clinic Participants (n=52 Type 2s) See a Sustained -1.5% A1c Decline Seven Months after VDC Discontinuation

• Medtronic Product Theater – First Look at Real-World Data From MiniMed 770G: Mean Time in Range of 71%; Gesture-Based Automatic Meal Detection With Klue

• Emory’s Dr. Francisco Pasquel Shares Experience With CGM in Inpatients With COVID-19: Effective at Achieving Glucose Control, While Reducing Encounters; Hybrid CGM/POC Protocol Recommended

• Barriers Associated with Disparities in Technology Use Among Black and Hispanic Young Adults with T1D; “Over 50%” of Study Participants were Never Offered Diabetes Technology

• Insulet’s Preschool Pivotal: Omnipod 5 in Young Children (Ages 2-<6) Drives 0.5% A1c Improvement, +2.6 Hours/Day Time in Range; No Recorded Severe Hypoglycemia or DKA Events

• Medtronic’s Extended-Wear Infusion Set Pivotal Shows Seven-Day Survival Rate of 75%; Participants Report Easier Insertion, More Comfort, and Higher Convenience

• Insulet Omnipod 5 Extension Phase Results Show Sustained A1c Reductions (7.2% to 6.7%) and Time in Range Improvements (+2.3 Hours/Day) Across Ages 14-70 at Six Months For All Ages

• Buckle Up for the Dexcom Symposium: KOLs Share a Plethora of Data on the Use of CGM in MDI and Basal-Only Type 2s, During Pregnancy, and in the Hospital Setting

• Is CGM Reliable Enough During Pregnancy? Dexcom G6 and FreeStyle Libre Report MARDs of 10.3% and 13.2% in Pregnant Women, Respectively; Prospective Trial of G6 Accuracy in Pregnancy to Complete Feb 2022 

• Omnipod 5 Associated with Significantly Improved Quality of Life Outcomes for Children and Teenagers with Diabetes and Their Parents; Parents of Children (Ages 6-<12) See Greatest Improvements

• Eversense Product Theater: Bridge Patient Access Program to Resume; Eversense Patient Ambassador Paul Reid on Using Eversense in Daily Life

• Social-Media Based Intervention Shows High Satisfaction, A1c Reduction from 7.4% to 6.8% in Low-Income, Older Immigrant Population; NYC’s Chinese Americans Perform Just ~4 Fingersticks/Week (!)

• InPen Initiation Associated With Slight Improvements In GMI and Time in Range For People With Type 1 or Type 2 Diabetes With Poor Baseline Control (GMI >8% And ≥9.5%); Users Still Spending Two-Thirds of Day in Hyperglycemia

• RCT of Children and Young Adult Type 1s (n=46) Sees +3.6 Hour/Day Improvement in Time in Range to 68% with CamAPS FX System; A1c Drops From 7.9% to 6.8%

• Real-World Retrospective EHR Review Shows Older Type 1s See +3.1 Hour/Day Increase in Time in Range to 77% Three Months Following Control-IQ Initiation

• Subgroup Analysis Shows FreeStyle Libre Userbase is Broader Than Dexcom’s: Higher Percentage of Users on Medicaid; Lower Percentage of Users Receive Diabetes Care from an Endocrinologist

• Real-World Observational Study Using Dexcom G6 and Fitbit Charge 3 Finds Each Additional Hour of Sleep is Associated with ~3 mg/dl Lower Daytime Mean Glucose in People Without Diabetes

• Drs. Anne Peters and Kasia Lipska Debate the Value of Digital Coaching for Patients with Type 2 Diabetes: Recognition of Potential, But Calls for More Robust Research and Evidence

• Dr. Leslie Eiland on Utilizing Telemedicine to Provide Diabetes Care in Rural Communities: Importance of Local Partnerships and Personalized Telemedicine Approaches

• International Diabetes Center Successfully Integrates Abbott LibreView Data with Epic EHR, Including AGP Report and Discrete Glucose Data; Potential Big Win for System if IDC is Used as Model

• Dexcom Drives A1c Drop from 10.1% to 7.1% (!) After Six Months in Type 2s on Basal-Only or Non-Insulin Therapy (n=38); Dr. Thomas Grace Calls for CGM to be “First-Line” Prescription for People With Diabetes

• Virta’s Medically Supervised Ketogenic Diet Associated With Massively Lower Rates of Hospitalization, Supplemental Oxygen, Ventilation, and Death From COVID-19 in People With Type 2 Diabetes

• Dr. Tom Martens Contextualizes the MOBILE Study of CGM in Type 2s on Basal-Only Insulin: CGM Works in Primary Care, But Has to be Supported by Proper Work Flows and Support

• Retrospective Chart Review of 555 Pediatric Type 1s Demonstrates Improved CGM Metrics During COVID-19: Mean Glucose Reduction from 193 mg/dl to 187 mg/dl; GMI reduction From 7.9% to 7.8%

• In-Patient CGM Reduces Time >250 mg/dl by 2.7 Hours/Day Compared to Point-of-Care BGM Testing in Hospitalized, Insulin-Requiring Type 2s (n=110)

• Feasibility Study of Capillary Bio’s SteadiSet Infusion Set Shows 88% Survival Out to Seven Days (n=41 sets); Close Concerns Q&A with CEO Paul Strasma

• Preclinical Study Finds that Medtronic’s “Duo,” A Dual Glucose-Sensing and Insulin-Infusing Device, Effectively Measures Glucose and Has 67% Seven-Day Survival Rate in Porcine Model (n=15 Wears); Human Feasibility Studies Ongoing

• “Don’t Let the Perfect Be the Enemy of the Good”: Dr. Bruce Buckingham Argues that Current AID Systems Achieve Strong Control Even with Missed Pre-Meal Boluses, Looks Ahead to Further Improvements with Fully Automated Insulin Delivery

• Provider Perspective on Supporting Patients on DIY Automated Insulin Delivery Systems with Natalie Bellini

Diabetes Big Picture Highlights

• Should Immune Intervention Trials Occur during the COVID-19 Pandemic? Drs. Carla Greenbaum and Adriana Weinberg Debate

• Hospitalizations for New Onset Pediatric Type 2 Diabetes Double During COVID-19 Pandemic, With Increased Severity of Hospitalizations

• The "MedStar Bootcamp": High-Risk Type 2s See a 3.1% A1c Drop to 8.1% after Three Months of DCES-Led Education, Support, and Care

• Regeneron-Sponsored Symposium Spotlights Preventing “Inevitable” Blindness Across the Spectrum of Diabetes Care

• Increased Awareness of Kidney Disease Among Providers and Patients Needed to Effectively Diagnose, Treat, and Prevent Disease Progression

• Provention Symposium Explains Benefits of Large-Scale Screening for Type 1 Risk on Heels of Teplizumab Ad Comm

• ADA CEO and President of Healthcare and Education Discuss Inequities in Diabetes

• SEARCH for Diabetes in Youth and TODAY Studies Highlight Disparities in Healthcare Coverage/Access Associated with Glycemic Control for Young Adults with T1D and T2D

• Seven-Year Follow-up of Youth in the SEARCH for Diabetes Youth Study Finds No Association Between Diabetes Autoantibodies and Clinical Metrics

• Preliminary Results from Post-Hoc Analysis of TN-10 Teplizumab Trial Suggest Proinsulin to C-Peptide Ratios Could Predict Treatment Responsivity

• Diabetes Operation Warp Speed – Why Not Now? Dr. Ruth Weinstock Reflects on Lessons the Past and the Present and Offers a Call to Action

• Banting Medal for Scientific Achievement Awarded to Dr. Jens Holst for Work on Incretins

• New Guidelines Alert: ADA/EASD 2021 Draft Consensus Report on the Management of Type 1 Diabetes in Adults Now Live; Public Comment Period Open Until July 8th

• ADA Presidents’ Select Abstract: BRAVO Model Finds BMI is the Most Important Target for Increasing Life Expectancy in Type 2 Diabetes

• Kelly West Award Lecture: Dr. Nick Wareham Emphasizes Role of Epidemiological Studies in Developing Preventative Measures

• DISCOVER Results Show 17% Global Use of SGLT-2 Inhibitors and GLP-1 Receptor Agonists, Primarily in People with Coronary Artery Disease

Top Abstracts

• Top 50 Oral Presentations

• Top 50 Posters

Day by Day Coverage

• ADA 2021 Exhibit Hall

• ADA 2021 Day #1

• ADA 2021 Day #2

• ADA 2021 Day #3

• ADA 2021 Day #4

• ADA 2021 Day #5 

• TCOYD/The diaTribe Foundation 14th Annual Diabetes Forum

Category Documents

The links below will go live as we publish each document leading up to ADA. For more on how to best use this resource, see our Category Document Tip Sheet.

• Diabetes Therapy:

  • SGLT Inhibitors: SGLT-2s, SGLT-1s, relevant combination therapies, and investigational indications.

  • GLP-1 Agonists: GLP-1s and relevant combination therapies.

  • Insulin: Insulin (injectable, oral, and inhaled) and relevant combination therapies.

  • Novel Therapies: New drug classes under investigation for diabetes, obesity, or related conditions. Includes novel glucagon formulations and dual agonists (e.g. GLP-1/glucagon).

  • DPP-4 Inhibitors: DPP-4s and relevant combination therapies.

• Diabetes Technology:

  • Glucose Monitoring: Continuous glucose monitoring (CGM), blood glucose monitoring (BGM), and flash glucose monitoring. 

  • Closing the Loop, Pumps, and Insulin Delivery: Automated insulin delivery, insulin pumps, patches, connected insulin pens, and other means of insulin delivery. 

  • Digital Health: telemedicine, mobile health, the Cloud, decision support, and online technologies.

• Other:

  • Beyond A1c and Hypoglycemia: Glycemic outcomes beyond A1c (time-in-ranges, glycemic variability), type 2 biomarkers/risk factors, patient-reported outcomes, hypoglycemia, and diabetes distress/mental health

  • Type 1 "Cure" Therapies, Adjuncts, and Pathophysiology: Cure-based topics and pathophysiology of type 1 diabetes, including predictors of the disease, prevention, and clinical data on cell-based therapies. This category also includes adjunct therapies for type 1 diabetes and beta cell biology

  • Obesity, Prediabetes, and Remission: Obesity therapies, bariatric surgery, adipocyte biology, nutritional interventions, exercise, prediabetes care, diabetes prevention, and efforts to reverse type 2 diabetes

  • Policy, Reimbursement, and Education: Models of care delivery for diabetes, treatment guidelines and algorithms, big picture information on the state of diabetes and diabetes care in the US and globally, and health disparities. Also includes select abstracts related to diabetes education and psychosocial support

  • Diabetes Complications: A curated collection of abstracts on diabetes complications, weighted towards nephropathy, retinopathy, macrovascular disease, gestational diabetes, and DKA

  • NAFLD/NASH: Includes abstracts related to the treatment of fatty liver disease and liver physiology

  • Opthalmology: Covers all abstracts on diabetic eye disease screening, prevalence and treatment. 

  • COVID-19: Featuring all abstracts related to COVID-19, spanning outcomes in people with diabetes to quarantine-related digital health interventions

• Late-Breaking Posters: A collection of abstracts from all disciplines listed above, specified for their findings' late breakthrough status